Skip to main content

An experimental drug could help fight memory loss in Alzheimer’s patients

An experimental drug that was developed to treat depression could also help battle the memory loss effects associated with Alzheimer’s disease, researchers from the University of California, Los Angeles have discovered. In tests involving mice, a team from UCLA’s Drug Discovery Lab showed that the “A03” drug increased brain levels of a particular enzyme which improves memory. The mice in the study had been genetically modified to have a protein called ApoE4, which is the most common genetic risk factor for Alzheimer’s. By giving them the drug, the researchers found that it resulted in improved memory, suggesting that it might be useful for cognitive improvement in Alzheimer’s patients.

“About two in three people with Alzheimer’s have the ApoE4 variant, and so this experimental drug candidate could be tested in human subjects after additional preclinical testing is completed, especially in Alzheimer’s patients carrying the ApoE4 variant,” Varghese John, a medicinal chemist and associate professor of Neurology at UCLA, told Digital Trends.

The mice in the study were treated for 56 days, during which they saw increased levels of the positive enzyme, called SirT1, in the hippocampus region of the brain one, of the main brain regions affected by Alzheimer’s. In addition, they found that the mice showed improvement in memory tests.

At present, an estimated 5.7 million Americans have Alzheimer’s disease. Worldwide, that number rises to around 50 million and someone in the world develops dementia every three seconds. Although there has been promising research in both ways to diagnose and potentially treat Alzheimer’s earlier on, so far there has been no proven cure or effective treatment that is capable of stopping its progression.

This latest piece of research is still at its relatively early stages, but if its findings can be replicated in humans it could turn out to be a game changer. To take this work forward, the researchers are now carrying out additional preclinical testing on A03 to evaluate its potential. They are also looking at variations of the drug to see if any of them are more effective than the parent molecule. Hopefully, a clinical trial will follow in the near future.

A paper describing the work was recently published in the journal Scientific Reports.

Editors' Recommendations

Luke Dormehl
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
IBM’s latest A.I. can help doctors detect how quickly a disease is progressing
ibm probabilistic ai huntingtons diseases doctor seeing patient

While there obviously shouldn't be an outcry for robots to take the jobs of human physicians, that doesn’t mean artificial intelligence can’t play an important role when it comes to helping doctors carry out certain aspects of their jobs -- such as recognizing early symptoms of serious diseases that can go unnoticed. A delay in diagnosis can make it more difficult to implement effective treatments or even find cures.

This is something that IBM wants to help with, courtesy of a new probabilistic A.I. model that can be used to better understand patients’ individual conditions and, crucially, how they are likely to develop. It can give information about a wide range of symptoms -- from shaking hands to mood swings -- and then use this data to help identify the biomarkers of diseases including diabetes, Huntington’s disease, Alzheimer’s, Parkinson’s, and more. The A.I. can help doctors understand more about the progression of these neurological disorders, as well as pinpoint how advanced they are.

Read more
Startup wants to reverse Parkinson’s and Alzheimer’s using human blood extract
alkahest parkinsons alzheimers trial elderly parkinson s patient

A cutting-edge startup is working on a treatment for neurodegenerative diseases such as Parkinson’s and Alzheimer’s by altering the concentration of plasma proteins in patients. This work is based on previous research from Stanford University indicating that cognitive decline in mice can be reversed through injections of blood taken from younger mice.

“Alkahest recently announced the initiation of a Phase 2 trial of its proprietary human plasma fraction, GRF6021, for the treatment of Parkinson’s disease with associated mild cognitive impairment or dementia,” Steven Braithwaite, Chief Scientific Officer at Alkahest, told Digital Trends. “As humans age, there is change in the makeup of the proteins in plasma. Some of the key, function-driving plasma proteins increase or decrease with time. At Alkahest, we have termed these changing proteins ‘chronokines.’”

Read more
Meet the game-changing pitching robot that can perfectly mimic any human throw
baseball hitter swings and misses

Who’s your favorite baseball pitcher? Shane McClanahan? Sandy Alcantara? Justin Verlander? Whoever you said, two of the top sports-tech companies in the U.S. -- Rapsodo and Trajekt Sports -- have teamed up to build a robot version of them, and the results are reportedly uncannily accurate.

Okay, so we’re not talking about walking-talking-pitching standalone robots, as great a sci-fi-tinged MLB ad as that would be. However, Rapsodo and Trajekt have combined their considerable powers to throw a slew of different technologies at the problem of building a machine that's able to accurately simulate the pitching style of whichever player you want to practice batting against -- and they may just have pulled it off, too.

Read more